Senior representatives from the pharmaceutical industry joined leading academics and members of Imperial Innovations and Imperial College London staff yesterday to launch Apollo Therapeutics at Imperial.
Apollo is a collaborative joint venture between leading pharmaceutical companies Johnson & Johnson, AstraZeneca and GlaxoSmithKline and the technology transfer offices of Imperial College London, Cambridge University and University College London. The £40 million initiative will provide translational funding for biomedical projects developed at these universities.
The aim of projects funded by Apollo is to develop promising intellectual property to the point at which it may be licensed out on commercial terms, and projects selected by Apollo will have access to the best industry-standard drug development expertise and development partners.
The Apollo Therapeutics launch event was held yesterday at 170 Queen’s Gate, hosted by Imperial Provost, Professor James Stirling. Members of staff from across the Faculties of Medicine and Natural Sciences met to hear presentations from Ian Tomlinson and Richard Butt, Chair and CEO (respectively) of Apollo Therapeutics, covering the reasons behind the formation of Apollo and the ways in which it will work to progress therapeutics innovations.